Mechanism of Action of JAKAFI
Hematology specialist Dr Harry Erba reviews the mechanism of action of JAKAFI, a JAK1 and JAK2 inhibitor, highlighting how JAKAFI works to inhibit overactive JAK pathway signaling. Dr Erba also discusses safety data from the RESPONSE trial, which compared JAKAFI to BAT for patients with PV who were either intolerant of or had an inadequate response to HU.